Project Grant R01CA288976
Award Date
12/3/24
Completion Date
11/30/29
Dollars Obligated
$496K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $147,486 to the University of Pittsburgh to conduct research on understanding the role of altered lipid metabolism in CD8 T cell exhaustion within the tumor microenvironment. The 3-year project aims to (1) evaluate the impact of abolishing citrate transport on carbon utilization and effector function of CD8 T cells in the tumor microenvironment, and (2) determine the role of stored...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $293,369 to Duke University to conduct research on mechanisms of macrophage-mediated immune evasion in residual tumors. The research aims to uncover potential strategies to target and engineer the immune-mediated clearance of residual tumor cells that can lead to cancer relapse, even after initial response to oncogene-targeted therapies. The award period runs from Aug 1, 2024 to Mar 31,...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $626,534 in funding to The Medical University of South Carolina to conduct research aimed at understanding how transient endoplasmic reticulum (ER) stress can enhance the anti-tumor function of T cells. The 5-year project, starting on December 1, 2024, will investigate the mechanisms by which ER stress-induced autophagy can improve mitochondrial function, metabolic programming, and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $602,881 to Duke University to develop novel immunotherapies using optimized tumor cell-penetrating antibodies. The primary objective is to translate these tumor cell-penetrating antibodies, which have demonstrated the ability to neutralize common oncogenic mutations like KRASG12D and control tumor growth, into the clinic. The research aims to elucidate the mechanisms...
The National Cancer Institute (NCI), under the Federal Grant Program "Cancer Treatment Research" (CFDA 93.395), awarded a $481,818 Project Grant to the University of Colorado-Denver. The grant, effective January 20, 2025 through December 31, 2029, aims to investigate inhibiting free fatty acid transport as a means to improve chimeric antigen receptor T-cell (CAR-T) therapy for relapsed B-cell acute lymphoblastic leukemia. The research will use genome-wide CRISPR/Cas9 screening,...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $563,233 to The Medical University of South Carolina to investigate strategies for overcoming immunosuppression and improving adoptive T cell therapy for cancer treatment. The key focus is on understanding how the sphingosine kinase 2 (SPHK2) and sphingosine-1-phosphate (S1P) axis regulates the suppressive function of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment....
This federal Project Grant award of $176,712 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research to investigate the role of CD91-mediated signaling in priming T cell responses to nascent, emerging tumors. The primary awardee, the University of Pittsburgh, will develop a new mouse model to test the importance of CD91-mediated signaling in response to tumor-derived heat shock proteins for cancer immunosurveillance. This research aims to advance the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $719,799 to Health Research, Inc. to investigate the impact of metabolic adaptations on the tumor microenvironment in metastatic triple-negative breast cancer (TNBC). The research aims to elucidate how the metabolic enzyme PFKFB4 regulates genetic and metabolic plasticity in the hypoxic tumor microenvironment, and how these adaptations impact immune suppression and metastatic...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $102,324.00 to The Medical University of South Carolina (MUSC) to elucidate the impact of peroxisome biogenesis on adaptive immune responses, particularly within the tumor microenvironment and anti-tumor immunity. The overarching goal is to understand how enhancing peroxisome capacity in T cells can improve their persistence and mitigate exhaustion when exposed to the immunosuppressive...
This $767,324 Cooperative Agreement award from the National Cancer Institute (NCI) under CFDA 93.396 - Cancer Biology Research is funding research at the Van Andel Research Institute (VAI) in Grand Rapids, Michigan. The research aims to understand how dietary caloric restriction can boost anti-tumor immunity by impacting the metabolism and fate of CD8 T cells in the tumor microenvironment. Specifically, the study will investigate how the balance between ketone bodies and fatty acids regulates...